Physician profile
William Avery Warnes
NPI 1710937636
$2,978.07
in general payments reported to CMS, 2019-2025
21 companies · $1,040 in 2025
The $1,040 reported for 2025 was more than what 86% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $570 · 2020: $29.11 · 2021: $80.93 · 2022: $519 · 2023: $558 · 2024: $181 · 2025: $1,040.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,779.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,778.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $770.97 | 2019-2025 | Invega Sustenna, Spravato |
| Otsuka America Pharmaceutical, INC. | $558.53 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Alkermes, INC. | $247.18 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Neurocrine Biosciences, INC. | $226.34 | 2019-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $224.30 | 2025 | Cobenfy |
| Abbvie INC. | $223.17 | 2023-2025 | Vraylar |
| Vanda Pharmaceuticals INC. | $125.66 | 2019-2025 | Hetlioz, Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $106.56 | 2023-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $84.49 | 2022-2025 | Austedo Xr |
| Corium, LLC | $72.87 | 2022-2023 | Azstarys |
| Indivior INC. | $53.94 | 2022-2023 | Perseris |
| Neuronetics, INC. | $47.57 | 2025 | Neurostar Tms Therapy System |
| Axsome Therapeutics, INC. | $44.41 | 2024-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $41.30 | 2020-2022 | |
| Lundbeck LLC | $41.18 | 2022-2025 | Rexulti |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $32.40 | 2022-2023 | Qelbree |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $23.66 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.50 | 2023 | Trintellix |
| Vertical Pharmaceuticals, LLC | $12.29 | 2019 | |
| Allergan, INC. | $11.46 | 2019 | |
| Avanir Pharmaceuticals, INC. | $11.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Warnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.